Tvardi Therapeutics Free Cash Flow (FCF) History (TVRD)

Tvardi Therapeutics reported −$19.4M in free cash flow for fiscal 2024, an increase of $75.1M from the previous fiscal year, with a free cash flow margin of −271.14%.

View full Tvardi Therapeutics company overview

Tvardi Therapeutics free cash flow by year

Tvardi Therapeutics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20242024-12-31−$19.4M$75.1M−271.14%
20232023-12-31−$94.5M−$15.7M−450.46%
20222022-12-31−$78.8M−$18.6M−188.15%
20212021-12-31−$60.1M−$54.3M−261.10%
20202020-12-31−$5.8M$103.4M−4.32%
20192019-12-31−$109.2M−$86.9M−549.35%
20182018-12-31−$22.4M$32.5M−166.11%
20172017-12-31−$54.9M−$6.8M−6024.70%
20162016-12-31−$48.1M−$26.6M−55927.91%
20152015-12-31−$21.5M−$3.8M−565.29%
20142014-12-31−$17.7M−$20.5M−556.63%
20132013-12-31$2.8M+23.60%

Tvardi Therapeutics free cash flow growth trends

Over the last five reported fiscal years, free cash flow grew from −$109.2M to −$19.4M, a net increase of $89.9M. Tvardi Therapeutics's latest reported quarter, Q4 2024, generated −$4.8M in free cash flow, an increase of $18.7M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Tvardi Therapeutics filings at SEC.gov ↗